Voltarol Back & Muscle Pain Relief 1.16% Gel, Voltarol Max Strength Pain Relief 2.32% Gel, Voltarol Joint & Back Pain Relief 2.32% Gel, Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel (diclofenac diethylammonium). Indications Local symptomatic relief of pain and inflammation in trauma of the tendons, ligaments, muscles and joints e.g. due to sprains, strains and bruises, and localised forms of soft tissue rheumatism. Osteoarthritis and Max Strength Gel only: Relief of pain of non-serious arthritic conditions. Dosage and method of use Adults and children aged 14 years and over. Gently rub 2-4 g into skin of affected site. If symptoms worsen or do not improve within 7 days, seek medical advice. Back & Muscle Gel: Apply 3-4 times daily for up to 7 days. Leave at least 4 hours between applications. No more than 4 applications in 24 hours. Maximum daily dose 16 g. Max Strength Pain Relief: Apply 2 times daily (morning and evening) for up to 14 days. Maximum daily dose 8 g. Not for use for longer than 14 days unless recommended by doctor. Joint & Back Pain Relief: Apply 2 times daily (morning and evening) for up to 7 days. Maximum daily dose 8 g. Not for use for longer than 7 days unless recommended by doctor. Osteoarthritis Gel: Apply 3-4 times daily for up to 14 days. Maximum daily dose 16 g. Not for use for longer than 14 days unless recommended by doctor. Consult doctor if more than two major joints affected. Contraindications Patients whose asthma, angioedema, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs. Hypersensitivity to diclofenac, aspirin, other NSAIDs or excipients. Third trimester of pregnancy. Children under 14 years. Precautions Do not use on large areas of skin and over a prolonged period. Do not smoke and avoid naked flames. Avoid excessive exposure to sunlight to avoid photosensitivity. Contains propylene glycol and butylhydroxytoluene which may cause skin irritation. Apply only to intact, non-diseased skin. Do not use with occlusion. Avoid ingestion or contact with eyes or mucous membranes. Caution in patients with previous or active peptic ulceration; suffering from/previous history of asthma or allergic disease. Discontinue use if skin rash develops. Caution with concomitant use of other diclofenac products or systemic NSAIDs. Side effects See SPCs for full details. Rash, erythema, pruritus, dermatitis, eczema. Hypersensitivity (including urticaria), angioedema. Asthma. Photosensitivity reactions. Desquamation, skin discolouration. Product licence number, legal category, pack size and RSP (excl. VAT) Back & Muscle Gel: PL 44673/0156 (GSL) 30 g £5.41, 50 g £7.49, 100 g £12.08. Max Strength Pain Gel: PL 44673/0154 (P), 30 g £7.08, 50 g £9.99, 100 g £15.58. Joint & Back Pain Gel: PL 44673/0160 (GSL), 30 g £7.08, 50 g £9.99. Osteoarthritis Gel: PL 44673/0155 (P), 30 g £5.41, 50 g £7.49, 100 g £12.08. PL holder Gels: Haleon UK Trading Limited, The Heights, Weybridge, KT13 0NY, U.K. Date of preparation: Jan 2024.
Voltarol One a Day Muscle Pain Relief 140mg Medicated Plaster (diclofenac sodium). Indications Local symptomatic relief of pain in acute strains, sprains or bruises of the extremities following blunt trauma. Dosage and method of use Adults and adolescents from 16 years of age: Apply one plaster to the painful area once daily. Maximum daily dose is 1 plaster, only one painful area can be treated at a time. Do not use for longer than 7 days. Elderly: Use with caution. If symptoms worsen or use is needed for more than 7 days, consult a doctor. Contraindications Hypersensitivity to diclofenac, aspirin, other NSAIDs or excipients. Patients whose asthma, angioedema, urticaria or acute rhinitis are precipitated by aspirin or other NSAIDs. Third trimester of pregnancy. Patients with an active peptic ulcer or damaged skin, whatever the lesion involved. Use in children under 16 years of age. Precautions The plaster must not come into contact with or be applied to the eyes or mucous membranes. Use the lowest dose for the shortest time. Bronchospasm may occur in patients who suffer or have previously suffered from bronchial asthma or allergies. Immediately stop treatment if a rash occurs. Warn patients against exposure to sunlight or solarium radiation after removal of the plaster to reduce risk of photosensitisation. Systemic adverse events cannot be excluded if the preparation is used on large areas of skin and over a prolonged period. Use with caution in patients with impaired renal, cardiac or hepatic function, a history of a peptic ulcer, inflammatory bowel disease or haemorrhagic diathesis. Use with caution in the elderly. Do not use with other diclofenac or NSAID medicinal products, topical or systemic. Contains butylated hydroxyanisole which may cause local skin reactions or irritations to the eyes and mucous membranes. Side effects Common: Rash, erythema, pruritus, dermatitis, eczema and application site reactions. All other side effects are rare or very rare, see SPC for full details. Product licence number, legal category, pack size and RSP (excl. VAT) PL 44673/0228, GSL, 2 pack £8.33, 5 pack £18.32 PL holder Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, U.K Date of revision September 2024.
Panmigrol Migraine Pain Relief 250 mg /250 mg /65 mg film coated tablets, Panmigrol Migraine and Headache Relief 250 mg /250 mg /65 mg film coated tablets (acetylsalicylic acid, paracetamol, caffeine). Indications: Acute treatment of headache and of migraine attacks with or without aura. Dosage and administration: Adults (18 years and over) only. Headache: 1 tablet; if needed an additional tablet can be taken. Intense pain: 2 tablets. If needed an additional 2 tablets can be taken with 4 to 6 hours between doses. For episodic use, up to 4 days for headache. Migraine: Take 2 tablets when symptoms appear. If needed an additional 2 tablets can be taken, with 4 to 6 hours between doses. Intended for episodic use, up to 3 days for migraine. Maximum 6 tablets in 24 hours. Drink a full glass of water with each dose. Not recommended for use in children under 18 years. Contraindications: Hypersensitivity to the active ingredients or excipients. Patients in whom attacks of asthma, bronchospasm, angioedema, urticaria, or acute rhinitis are precipitated by aspirin or other NSAIDs. Active gastric or intestinal ulcer, gastrointestinal bleeding, or perforation and in patients with a history of peptic ulceration. Haemophilia or other haemorrhagic disorders. Severe cardiac, hepatic, or renal impairment or failure. Intake of more than 15 mg methotrexate per week. Third trimester of pregnancy. Precautions: Do not use with systemic NSAIDs, anticoagulants, medicines that inhibit platelet aggregation, aspirin-containing or paracetamol-containing products or alcohol; if vomiting occurs with > 20% of migraines or bedrest is needed with >50% of migraine attacks; for more than 10 days per month for more than 3 months. Discontinue use immediately in suspected medication overuse headaches, gastrointestinal bleeds, or ulceration. GI bleeds / ulceration generally have more serious consequences in the elderly. Use special precaution in those with bronchial asthma, seasonal allergic rhinitis, nasal polyps, chronic obstructive pulmonary disease, or chronic infection of the respiratory tract. Use caution in undiagnosed migraineurs, or those with atypical symptoms, exclude other neurological conditions; patients with dehydration, gout, reduced uric acid excretion, congestive heart failure, impaired renal or hepatic function/disease, those with depleted glutathione levels e.g. severely malnourished, anorexic, low body mass index, sepsis, uncontrolled hypertension, severe glucose 6-phosphate dehydrogenase deficiency, diabetes mellitus, defects of haemostasis (monitoring is advised), metrorrhagia, menorrhagia, alcohol dependence, hyperthyroidism (may interfere with thyroid tests), arrhythmia. May mask the signs and symptoms of infection, increase bleeding tendency during/after surgery. Caution, regarding paracetamol, if used at therapeutic doses for a prolonged period or administered concomitantly with flucloxacillin due to increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism). If suspected, discontinue use promptly and monitor closely, including measurement of urinary 5-oxoproline. Also use with caution if used with other potentially hepatotoxic medicinal products or products that induce liver microsomal enzymes. Should not be given to children and adolescents aged under 18 years unless specifically indicated because there is a possible association between acetylsalicylic acid and Reye’s syndrome. Limit use of caffeine containing products. If no migraine relief from first 2-tablet dose, seek advice from physician. Contains 0.03mg benzoic acid per tablet. Side effects: Common: Nervousness, dizziness, nausea, abdominal discomfort. For full side effects please see summary of product characteristics. Legal category and RRP (excl. VAT): GSL: £3.13 P: £5.21 Product licence number: GSL: PL 44673/0229, P: PL 44673/0231 Product licence holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, United Kingdom. Text prepared: Feb 2025.
Panadol 500 mg capsules, soft (Paracetamol) Indications: For the treatment of most painful and febrile conditions, including headache, migraine, backache, toothache, rheumatic pain and dysmenorrhoea as well as for relief of the symptoms of colds, influenza and sore throat. Symptomatic relief of pain due to non-serious arthritis. Dosage and administration: Adults and children, 16 years and over: One or Two capsules up to four times daily as required. Max. 8 capsules in 24 hours. Children 10-15 years: One tablet four times daily as required. Max. 4 tablets in 24 hours. Children under 10 years: Not recommended. Take with enough water. Stop treatment if pain lasts longer than 5 days or fever lasts longer than 3 days and seek doctor’s advice. Doses should not be repeated more frequently than every 4 hours. Contraindications: Known hypersensitivity to any of the ingredients. Warnings and Precautions: Do not use long-term or frequently except under medical supervision. Long-term use (> 3 months) of analgesics with intake every other day or more frequently, headache can occur or become worse. Do not use with any other paracetamol-containing products. Reconsider treatment in the case of a high fever, symptoms of secondary infection or the persistence of symptoms. Seek immediate medical advice if several daily doses taken at once and patient feels unwell. Use with caution in those with renal or hepatic impairment, acute hepatitis, the concomitant administration of medicinal products which have an influence on hepatic function, glucose-6-phosphate dehydrogenase deficiency, haemolytic anaemia, alcohol abuse, chronic alcoholism, dehydration and chronic malnutrition, asthmatics who are sensitive to acetylsalicylic. For children a treatment of 60 mg/kg/day of paracetamol combined with another antipyretic is not allowed, unless due to a lack of efficacy. Use with caution in patients with glutathione depletion due to metabolic deficiencies. Caution, regarding paracetamol, if used at therapeutic doses for a prolonged period or administered concomitantly with flucloxacillin due to increased risk of high anion gap metabolic acidosis (HAGMA), particularly in patients with severe renal impairment, sepsis, malnutrition and other sources of glutathione deficiency (e.g. chronic alcoholism). If suspected, discontinue use promptly and monitor closely, including measurement of urinary 5-oxoproline. Patients with non-serious arthritis who need to take painkillers every day should consult a doctor. Contains 108mg sorbitol per capsule. Patients with rare hereditary problems of fructose intolerance should seek medical advice before taking this medicine. Side effects: Very rare: Thrombocytopenia, agranulocytosis, anaphylaxis, cutaneous hypersensitivity reactions including skin rash, and angioedema. Bronchospasm and hepatic dysfunction. Not known: high anion gap metabolic acidosis due to pyroglutamic acidosis in patients with risk factors. Legal category and RRP (excl. VAT): GSL: 16s £3.96 Product licence number: PL 44673/0233 Product licence holder: Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, United Kingdom. Text prepared: Jan 2025.
